The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Tislelizumab is now approved in nine indications in China
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Subscribe To Our Newsletter & Stay Updated
